-
公开(公告)号：WO2020017911A1
公开(公告)日：2020-01-23
申请号：PCT/KR2019/008910
申请日：2019-07-18
Abstract: 본 발명은 원하는 위치에 주사기를 통해 약물을 투여하기 위한 소동물 뇌실내 투여 보정기에 관한 것이다. 본 발명은 주사기(S) 바늘이 삽입되는 가이드홀(1120)이 형성된 가이드부(1100), 내측로 형성된 상측캐비티(1210) 및 상부측에 상기 가이드부(1120)가 안착되도록 마련된 크래들(1220)을 포함하는 몸체(1200), 상기 몸체(1200)와 일체로 형성되거나, 별도 마련될 수 있으며, 상기 상측캐비티(1210)와 대응되어 소동물의 두부가 출입될 수 있도록 내부에 두부수용공간(1230)이 형성되도록 마련된 하측캐비티(1310)를 포함하는 고정부(1300)를 포함한다.
-
公开(公告)号：KR1020050082070A
公开(公告)日：2005-08-22
申请号：KR1020040010429
申请日：2004-02-17
Applicant: 한국화학연구원
IPC: G01N33/53
CPC classification number: G01N33/5088 , A61B5/0402 , A61B5/4845
Abstract: 본 발명은 약물의 심부정맥 유발 위해성 분석방법에 관한 것으로서, 보다 구체적으로는 1) 동물로부터 심장을 분리하는 단계; 2) 단계 1에서 분리한 심장으로부터 심근조직을 분리하는 단계; 3) 단계 2에서 분리한 심근조직을 일정한 수위의 관류(Normal Tyrode) 용액을 포함하고, 상기 용액의 출렁임을 방지하는 챔버에 담그는 단계; 4) 단계 3에서 챔버에 담근 심근조직을 실리콘이 코팅된 플레이트 바닥에 고정시키는 단계; 및 5) 단계 4의 고정된 심근조직에 약물을 처리한 뒤 활동전위를 측정하는 단계를 포함하는 약물의 심부정맥 유발 위해성 분석방법에 관한 것이다. 본 발명의 분석방법은 심장발작 등에 영향을 줄 수 있는 약물의 효능을 검사하는데 유용하게 사용될 수 있다.
-
公开(公告)号：KR1020050002286A
公开(公告)日：2005-01-07
申请号：KR1020030043657
申请日：2003-06-30
Applicant: 한국화학연구원
IPC: A01K67/027
CPC classification number: A01K67/0275 , A01K2227/105 , C12N15/09
Abstract: PURPOSE: An inherited deformity of a hindlimb mouse which has a club foot derived using a chemical material, ENU(N-ethyl-N-nitrosourea) and method for producing the same are provided. CONSTITUTION: The inherited deformity of the hindlimb mouse has the club foot derived using the ENU. The mouse is prepared by a random mutagenesis. The method for producing the same comprises the steps of: inducing a mutation by inputting ENU to a male mouse; producing 3-generation mouse by crossing the mouse having the mutation with a normal mouse, crossing an obtained 1-generation mouse with a normal mouse and backcrossing an obtained 2-generation mouse with the 1-generation mouse; and screening a mouse having the club foot symptom from the 3-generation mouse.
Abstract translation: 目的：提供使用化学物质ENU（N-乙基-N-亚硝基脲）衍生的具有球杆脚的后肢小鼠的遗传畸形及其制造方法。 构成：后肢小鼠的继承畸形具有使用ENU的球杆脚。 小鼠通过随机诱变制备。 其制造方法包括以下步骤：通过向雄性小鼠输入ENU来诱导突变; 通过与正常小鼠杂交具有突变的小鼠产生3代小鼠，将所获得的1代小鼠与正常小鼠杂交，并与所述第1代小鼠回交获得的2代小鼠; 并筛选来自3代小鼠具有足球症状的小鼠。
-
公开(公告)号：KR1020040081843A
公开(公告)日：2004-09-23
申请号：KR1020030016392
申请日：2003-03-17
Applicant: 한국화학연구원
IPC: A01K67/027
CPC classification number: A01K67/0276 , A01K2227/105 , C12N15/09
Abstract: PURPOSE: Provided is a head tossing and circling mutant mouse that can be utilized in the research and the development of therapeutic agents for diseases associated with an organ of hearing and balancing, central nerves and a nerves system. CONSTITUTION: The head tossing and circling mutant mouse is produced by the process comprising the steps of: administering N-ethyl-N-nitrosourea into a male mouse; cross-breeding the above mouse with a normal mouse to obtain a 2nd generation mouse; back cross-breeding the obtained 2nd generation mouse with the above 1st generation mouse to obtain a 3rd generation mouse; and screening the mouse which exhibits head tossing and circling action from the obtained 3rd generation mouse. Particularly, the mouse is Musmusculus of BALB/c and N-ethyl-N-nitrosurea is administered in a concentration of 150 to 250 mg/kg.
Abstract translation: 目的：提供一种可以用于研究和开发与听力和平衡器官相关的疾病，中枢神经和神经系统的治疗剂的头部折叠和盘旋的突变体小鼠。 构成：通过包括以下步骤的方法产生头部折叠和盘旋的突变小鼠：向雄性小鼠施用N-乙基-N-亚硝基脲; 用正常小鼠杂交上述小鼠以获得第二代小鼠; 使用上述第1代小鼠将获得的第2代小鼠交叉繁殖，获得第3代小鼠; 并从所获得的第三代小鼠筛选显示头部抛掷和盘旋动作的小鼠。 特别地，小鼠是BALB / c的Musmusculus，并且以150-250mg / kg的浓度施用N-乙基-N-亚硝基脲。
-
公开(公告)号：KR1020040029893A
公开(公告)日：2004-04-08
申请号：KR1020020060334
申请日：2002-10-02
Applicant: 한국화학연구원
IPC: A01K67/027
CPC classification number: A01K67/0275 , A01K2227/105 , A01K2267/0362 , C12N15/8509
Abstract: PURPOSE: Provided is a mutant mouse having hereditary cataract observable with naked eyes, which is useful as an excellent cataract model animal in diagnosis, prevention and treatment of cataract. CONSTITUTION: The mutant mouse having hereditary cataract is produced by random mutagenesis using N-ethyl-N-nitrosourea(ENU). Particularly, the mouse is a Mus musculus of a BALB/c line. The method for making the mutant mouse comprises the steps of: administering ENU to a male mouse to cause mutagenesis; hybridizing the mutant mouse with a normal mouse to obtain a first-generation mouse, hybridizing the first-generation mouse with a normal mouse to obtain a second-generation mouse, and counter-hybridizing the first-generation mouse with the second-generation mouse to obtain a third-generation mouse; and screening a mouse showing a cataract symptom from the third-generation mice.
Abstract translation: 目的：提供一种具有裸眼观察的遗传性白内障的突变型小鼠，可用作白内障诊断，预防和治疗中优良的白内障模型动物。 构成：具有遗传性白内障的突变小鼠通过使用N-乙基-N-亚硝基脲（ENU）的随机诱变产生。 特别地，鼠标是BALB / c线的Mus musculus。 制备突变小鼠的方法包括以下步骤：向雄性小鼠施用ENU以引起诱变; 将突变小鼠与正常小鼠杂交以获得第一代小鼠，将第一代小鼠与正常小鼠杂交以获得第二代小鼠，并将第一代小鼠与第二代小鼠逆化杂交至 获得第三代鼠标; 并筛选显示来自第三代小鼠的白内障症状的小鼠。
-
Patent Agency Ranking
公开(公告)号：KR100733913B1
公开(公告)日：2007-07-02
申请号：KR1020050080137
申请日：2005-08-30
Applicant: 한국화학연구원
IPC: A61K31/352
Abstract: 본 발명은 안토시아닌을 포함하는 뇌세포 보호제와 뇌경색 및 뇌졸중 예방 또는 치료제에 관한 것으로서, 본 발명의 안토시아닌은 뇌세포 보호 효과를 나타내어, 뇌경색 및 뇌졸중 예방 또는 치료제로 이용할 수 있다.
-
公开(公告)号：KR1020070028640A
公开(公告)日：2007-03-13
申请号：KR1020050080137
申请日：2005-08-30
Applicant: 한국화학연구원
IPC: A61K31/352
Abstract: A composition comprising anthocyanin is provided to be able to be used as a prophylactic or therapeutic agent for cerebral infarction and stroke by using brain cell protecting effect of the anthocyanin. The brain cell protecting agent comprises at least one anthocyanin represented by the formula(1), wherein each R1 to R7 is independently H, OH, OCH3, provided that the R4 and R5 may include sugar such as glucose, galactose, mannose, and xylose. The anthocyanin is selected from the group consisting of cyanidin, delphinidin, malvidin, pelargonidin, peonidin, and petunidin.
Abstract translation: 提供了包含花青素的组合物，以能够通过使用花青素的脑细胞保护作用用作脑梗塞和中风的预防或治疗剂。 脑细胞保护剂包含至少一种由式（1）表示的花青素，其中每个R 1至R 7独立地为H，OH，OCH 3，条件是R 4和R 5可包括糖如葡萄糖，半乳糖，甘露糖和木糖 。 花青素选自花青素，花翠素，麦芽糖苷，天竺葵素，花生四烯素和矮牵牛。
-
公开(公告)号：KR100620123B1
公开(公告)日：2006-09-13
申请号：KR1020040010429
申请日：2004-02-17
Applicant: 한국화학연구원
IPC: G01N33/53
Abstract: 본 발명은 약물의 심부정맥 유발 위해성 분석방법에 관한 것으로서, 보다 구체적으로는 1) 동물로부터 심장을 분리하는 단계; 2) 단계 1에서 분리한 심장으로부터 심근조직을 분리하는 단계; 3) 단계 2에서 분리한 심근조직을 일정한 수위의 관류(Normal Tyrode) 용액을 포함하고, 상기 용액의 출렁임을 방지하는 챔버에 담그는 단계; 4) 단계 3에서 챔버에 담근 심근조직을 실리콘이 코팅된 플레이트 바닥에 고정시키는 단계; 및 5) 단계 4의 고정된 심근조직에 약물을 처리한 뒤 활동전위를 측정하는 단계를 포함하는 약물의 심부정맥 유발 위해성 분석방법에 관한 것이다. 본 발명의 분석방법은 심장발작 등에 영향을 줄 수 있는 약물의 효능을 검사하는데 유용하게 사용될 수 있다.
-
公开(公告)号：KR1020040029894A
公开(公告)日：2004-04-08
申请号：KR1020020060335
申请日：2002-10-02
Applicant: 한국화학연구원
IPC: A01K67/02
CPC classification number: A01K67/0275 , A01K2227/105 , A01K2267/0306 , C12N5/0625
Abstract: PURPOSE: Provided is a mutant mouse having hereditary atrichia, which is useful as an excellent atrichia model animal in researches related to a mechanism, diagnosis, prevention and treatment of atrichia and depilation. CONSTITUTION: The mutant mouse having hereditary atrichia is produced by random mutagenesis using N-ethyl-N-nitrosourea(ENU). Particularly, the mouse is a Mus musculus of a BALB/c line. The method for making the mutant mouse comprises the steps of: administering ENU to a male mouse to cause mutagenesis; hybridizing the mutant mouse with a normal mouse to obtain a first-generation mouse; and screening a mouse showing an atrichia symptom from the first-generation mice.
Abstract translation: 目的：提供一种具有遗传性无精症的突变型小鼠，在与无菌和脱毛的机制，诊断，预防和治疗相关的研究中可用作优异的无精养模型动物。 构成：通过使用N-乙基-N-亚硝基脲（ENU）的随机诱变产生具有遗传性无精子症的突变体小鼠。 特别地，鼠标是BALB / c线的Mus musculus。 制备突变小鼠的方法包括以下步骤：向雄性小鼠施用ENU以引起诱变; 将突变小鼠与正常小鼠杂交以获得第一代小鼠; 并筛选显示来自第一代小鼠的无血症症状的小鼠。
-
公开(公告)号：KR100857188B1
公开(公告)日：2008-09-05
申请号：KR1020070047144
申请日：2007-05-15
Applicant: 한국화학연구원
CPC classification number: A61M5/172 , A61M5/16813 , A61M2205/52
Abstract: A drug administration controller is provided to administer an automatically calculated dose by weight of each experimental animal, thereby improving accuracy and rapidity of an experiment and further reliability of experiment results. A drug administration controller comprises a drug feeder(1), a drug administrator(3), and a dose controller(5). The drug feeder includes a drug container(7), a dispenser(9), and a valve(11) for regulating the amount of drug to be dispensed. The drug administrator includes an administration switch(15), an image recording unit(17) for recording oral and inhalation administration sites, and a display(19). The dose controller includes a controller(C), a dose storage database(21) controlled by the controller, an image storage database(23), and a backup data storage database(25). The controller includes a processing module with a program to calculate a required dose using a preset equation and weight of a target animal for experiment.
Abstract translation: 提供药物管理控制器，以实施每个实验动物的自动计算剂量，从而提高实验的准确性和快速性以及实验结果的进一步可靠性。 药物管理控制器包括药物供给器（1），药物管理者（3）和剂量控制器（5）。 药物供给器包括药物容器（7），分配器（9）和用于调节待分配药物量的阀（11）。 药物管理员包括管理开关（15），用于记录口服和吸入管理部位的图像记录单元（17）和显示器（19）。 剂量控制器包括控制器（C），由控制器控制的剂量存储数据库（21），图像存储数据库（23）和备份数据存储数据库（25）。 控制器包括具有程序的处理模块，用于使用目标动物的预设方程和重量来计算所需剂量用于实验。
-
-
-
-
-
-
-
-
-
Search Results
27
records
(took 0.021 seconds)
